Comparison of CISNE and MASCC Score in Predicting Complications on Post Chemotherapy Febrile Neutropenia

Abstract Objective Despite the routine use of MASCC score in febrile neutropenia patients, researches showed that serious complications still occur in 15-42% of low-risk patients; therefore, a new scoring system Clinical Index of Stable Febrile Neutropenia (CISNE) is developed to predict the complication better. This retrospective cohort study aimed to assess the role of CISNE score compared to MASCC score as a risk stratification in post-chemotherapy FN in solid and hematologic malignancy. Patients who underwent inpatient treatment with FN between July 2015 and December 2019 were grouped based on both scores, while complications during inpatient was recorded. Both score's areas under the receiver operating characteristics curve were compared using DeLong method. Results CISNE score showed a better performance both in solid malignancy with AUC of CISNE score (0.893; 95% CI 0.829 - 0.95, p = 0.03) compared to AUC of MASCC score (0.77; 95% CI 0.68 – 0,86, p = 0.04) and in hematologic malignancy with AUC of CISNE score (0.91; 95% CI 0.84 - 0.97, p = 0.03) and AUC MASCC score (0.735 ; 95% CI 0.68 - 0.86, p = 0.04). CISNE score showed a better diagnostic performance with cut-off point value of 2.